×
About 91,394 results
Evidence Mounts for Bariatric Benefit in Obesity-Related Cancer
https://www.medscape.com/viewarticle/921110
Medscape Busko, M

Nov 11th, 2019 - Two studies that provide further support for a potential benefit of a reduced risk of obesity-related cancers post-bariatric surgery were presented here at Obesity Week 2019.

Pediatric Metabolic and Bariatric Surgery: Evidence, Barriers, and Best Practices
https://pediatrics.aappublications.org/content/early/2019/10/24/peds.2019-3223
Pediatrics Armstrong, S. et. al.

Oct 27th, 2019 - Severe obesity among youth is an “epidemic within an epidemic” and portends a shortened life expectancy for today’s children compared with those of their parents’ generation. Severe obesity has outpaced less severe forms of childhood obesity in prevalence, and it disproportionately affects adolescents. Emerging evidence has linked severe obesity to the development and progression of multiple co...

Chronic inflammatory liver diseases and coffee intake
https://journals.lww.com/co-clinicalnutrition/Abstract/publishahead/Chronic_inflammatory_liver_diseases_and_coffee.99131.aspx
Current Opinion in Clinical Nutrition & Metabolic Care; Contaldo, F. et. al.

Jun 17th, 2019 - Purpose of review To review the healthy protective effects of coffee against several metabolic diseases and some types of cancer. In this short review, the possible preventive and/or therapeutic actions of coffee on liver function is focused. Recent findings The protective mechanisms of coffee are various and because of several components with anti-inflammatory and antioxidant properties in ...

FDA approves ramucirumab for hepatocellular carcinoma
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-hepatocellular-carcinoma

May 9th, 2019 - On May 10, 2019, the Food and Drug Administration approved ramucirumab (CYRAMZA®, Eli Lilly and Company) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib.

Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
https://jnccn.org/view/journals/jnccn/17/4/article-p302.xml
Benson, A. et. al.

Mar 31st, 2019 - Incidence and mortality rates for cancer overall are declining, but both incidence and mortality rates for hepatocellular carcinoma (HCC) are increasing.1,2 Risk factors for development of HCC include infection with hepatitis B virus (HBV) and/or hepatitis C virus (HCV), and cirrhosis of the liver (eg, alcohol cirrhosis).3 Metabolic disorders (ie, obesity, diabetes, impaired glucose metabolism,...

Appendicitis - StatPearls
https://www.ncbi.nlm.nih.gov/books/NBK493193/

Feb 21st, 2019 - Appendicitis is inflammation of the vermiform appendix. This is a hollow organ located at the tip of the cecum, usually in the right lower quadrant of the abdomen.

Hepatitis, Nonalcoholic Steatohepatitis
https://www.ncbi.nlm.nih.gov/books/NBK470243/
Sharma, B. et. al.

Jan 31st, 2019 - Nonalcoholic, fatty liver disease (NAFLD) is defined as the ectopic accumulation of fat in the liver (hepatic steatosis) when no other causes of secondary, liver fat accumulation are present. As minor deposition of fat can occur in healthy adults, deposition of fat in at least 5% of hepatocytes is considered pathologic. Nonalcoholic steatohepatitis (NASH) is diagnosed via a liver biopsy when th...

Ramucirumab After Sorafenib in Patients With Advanced HCC and Increased α-Fetoprotein Concentrations
https://www.practiceupdate.com/c/78793/2/1
Grothey, A.

Jan 22nd, 2019 - The landscape of systemic therapy of hepatocellular carcinoma (HCC) has dramatically changed in the last 5 years with the introduction of various active agents into clinical pathways. The latest addition of agents with proof-of-efficacy in HCC is ramucirumab, an antibody against VEGF-R2. The published results of the REACH-2 trial in patients with prior sorafenib therapy demonstrate increased ov...

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
https://www.thelancet.com/action/showPdf?pii=S1470-2045%2818%2930937-9
Zhu, A. et. al.

Jan 17th, 2019 - Patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations have poor prognosis. We aimed to establish the efficacy of ramucirumab in patients with advanced hepatocellular carcinoma and α-fetoprotein concentrations of 400 ng/mL or higher.

Direct-Acting Antiviral Therapy not Associated with Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study
https://www.gastrojournal.org/article/S0016-5085(19)30057-5/pdf
Singal, A. et. al.

Jan 16th, 2019 - Background & Aims There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA-treated and untreated HCV-infected patients who had achieved a complete response to HCC treatment in a North American cohort.

Appendicitis - Merck Manual
https://www.merckmanuals.com/professional/gastrointestinal-disorders/acute-abdomen-and-surgical-gastroenterology/appendicitis

Nov 30th, 2018 - Appendicitis is acute inflammation of the vermiform appendix, typically resulting in abdominal pain, anorexia, and abdominal tenderness. Diagnosis is clinical, often supplemented by CT or ultrasonography. Treatment is surgical removal of the appendix

ASMBS updated position statement on bariatric surgery in class I obesity (BMI 30–35 kg/m2)
https://asmbs.org/app/uploads/2018/08/PIIS1550728918302934-Low-BMI.pdf

Jul 31st, 2018 - The American Society for Metabolic and Bariatric Surgery (ASMBS) issued a position statement on the role of bariatric surgery in class I obesity in 2012 [1]. That statement was developed in response to inquiries made to the ASMBS by society members, physicians, patients, hospitals, health insurance payers, policymakers, and the media regarding the safety and efficacy of bariatric surgery f...

Association of Bariatric Surgery vs Medical Obesity Treatment With Long-term Medical Co...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833560
JAMA Jakobsen GS, Småstuen MC et. al.

Jan 17th, 2018 - The association of bariatric surgery and specialized medical obesity treatment with beneficial and detrimental outcomes remains uncertain. To compare changes in obesity-related comorbidities in patients with severe obesity (body mass index ≥40 or ≥35 and at least 1 comorbidity) undergoing bariatric surgery or specialized medical treatment. Cohort study with baseline data of exposures from Novem...

Contraception and Conception After Bariatric Surgery.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5679259
Obstetrics and Gynecology; Menke MN, King WC et. al.

Oct 10th, 2017 - To examine contraceptive practices and conception rates after bariatric surgery. The Longitudinal Assessment of Bariatric Surgery-2 is a multicenter, prospective cohort study of adults undergoing first-time bariatric surgery as part of routine clinical care at 10 U.S. hospitals. Recruitment occurred between 2005 and 2009. Participants completed preoperative and annual postsurgical assessments f...

Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospecti...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662845
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology; Reiss KA, Yu S et. al.

Sep 5th, 2017 - Purpose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for patients with advanced hepatocellular carcinoma. There are few data examining how sorafenib starting dose may influence patient outcomes and costs. Patients and Methods We retrospectively evaluated 4,903 patients from 128 Veterans Health Administration hospitals who were prescribed sorafenib for...

Risk of Abdominal Surgery in Pregnancy Among Women Who Have Undergone Bariatric Surgery.
https://doi.org/10.1097/AOG.0000000000001975
Obstetrics and Gynecology; Stuart A, Källen K

Apr 6th, 2017 - To compare the rates of abdominal surgery during pregnancy among women with previous bariatric surgery (women in the case group) and women with first-trimester body mass index (BMI) greater than 35 and no previous bariatric surgery (women in the control group). We conducted a national cohort study, merging data from the Swedish Medical Birth Registry and the Swedish National Patient Registry, c...

Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664153
Gastroenterology Serper M, Taddei TH et. al.

Mar 11th, 2017 - Little is known about provider and health system factors that affect receipt of active therapy and outcomes of patients with hepatocellular carcinoma (HCC). We investigated patient, provider, and health system factors associated with receipt of active HCC therapy and overall survival. We performed a national, retrospective cohort study of all patients diagnosed with HCC from January 1, 2008 thr...

Stereotactic body radiotherapy vs. TACE or RFA as a bridge to transplant in patients wi...
https://doi.org/10.1016/j.jhep.2017.02.022
Journal of Hepatology; Sapisochin G, Barry A et. al.

Mar 4th, 2017 - There is limited information on the use of stereotactic body radiotherapy (SBRT) as a bridge to liver transplantation for hepatocellular carcinoma and no study comparing its efficacy to transarterial chemoembolization (TACE) and radiofrequency ablation (RFA). We aimed to ascertain the safety and efficacy of SBRT on an intention-to-treat basis compared with TACE and RFA as a bridge to liver tran...

Long-term outcomes of bariatric surgery in adolescents with severe obesity (FABS-5+): a...
https://doi.org/10.1016/S2213-8587(16)30315-1
The Lancet. Diabetes & Endocrinology; Inge TH, Jenkins TM et. al.

Jan 9th, 2017 - Little is known about the long-term outcomes of bariatric surgery for severe adolescent obesity, raising questions about the durability of early responses to surgery. We aimed to analyse long-term (>5 years) outcomes of Roux-en-Y gastric bypass in a cohort of young adults who had undergone the operation during adolescence, in the Follow-up of Adolescent Bariatric Surgery at 5 Plus Years (FABS-5...

Changes in Functional Mobility and Musculoskeletal Pain After Bariatric Surgery in Teen...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5904853
JAMA Pediatrics; Ryder JR, Edwards NM et. al.

Jul 18th, 2016 - Severe obesity is associated with mobility limitations and higher incidence of multijoint musculoskeletal pain. It is unknown whether substantial weight loss improves these important outcomes in adolescents with severe obesity. To examine the association of bariatric surgery with functional mobility and musculoskeletal pain in adolescents with severe obesity up to 2 years after surgery. The Tee...